Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pimecrolimus. Novartis.

Rudolf E Schopf1

  • 1Johannes Gutenberg University, Department of Dermatology, Mainz, Germany. schopf@hautklinik.klinik.uni-mainz.de

Current Opinion in Investigational Drugs (London, England : 2000)
|July 2, 2002
PubMed
Summary

Pimecrolimus, a T-cell inhibitor, offers a non-steroid topical treatment for atopic dermatitis. Approved in the US and Denmark, it targets various dermatitis types in patients aged 3 months and older.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Severity of psoriasis and its impact on patient-reported outcomes (PROs): real world evidence with brodalumab 210 mg from the LIBERO study.

The Journal of dermatological treatment·2025
Same author

PPMS onset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders.

Therapeutic advances in neurological disorders·2020
Same author

Human epidermal Langerhans cells replenish skin xenografts and are depleted by alloreactive T cells in vivo.

Journal of immunology (Baltimore, Md. : 1950)·2011
Same author

Treatment of psoriasis with fumaric acid esters (Fumaderm).

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2007
Same author

A highly decreased binding of cyclic adenosine monophosphate to protein kinase A in erythrocyte membranes is specific for active psoriasis.

The Journal of investigative dermatology·2002
Same author

Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab.

Journal of the American Academy of Dermatology·2002

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Pimecrolimus is a macrolactam derivative of ascomycin.
  • It functions as an inhibitor of T-cell and mast-cell activation.
  • Novartis developed pimecrolimus for treating psoriasis and various forms of dermatitis.

Purpose of the Study:

  • To introduce pimecrolimus as a novel therapeutic agent.
  • To highlight its approval and market launch for atopic dermatitis.
  • To present its potential for treating other inflammatory skin conditions.

Main Methods:

  • Topical formulation development and approval processes.
  • Clinical evaluation for efficacy and safety in patients with atopic dermatitis.
  • Market analysis and sales forecasting by financial institutions.

Main Results:

  • US launch in February 2002 for mild-to-moderate atopic dermatitis (patients ≥2 years).
  • Danish approval in March 2002, allowing use in patients from 3 months of age.
  • Anticipated global approvals and significant sales projections from financial analysts.

Conclusions:

  • Pimecrolimus represents a significant advancement in non-steroid topical dermatitis treatment.
  • Its early approval and broad age indication underscore its therapeutic potential.
  • Market forecasts indicate strong commercial expectations for pimecrolimus.

Related Experiment Videos